Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Canakinumab in SJIA
NCT00891046Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2009
- Primary completion
- Dec 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of canakinumab in systemic juvenile idiopathic arthritis (SJIA), sponsored by Novartis. Started Sep 2009; status: completed.
02
Drugs
canakinumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NCT00891046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00891046.